University of Iowa Holden Comprehensive Cancer Center | Strategic Alliance Partners

Latest from University of Iowa Holden Comprehensive Cancer Center


MRD and ctDNA Could Shift into Larger Role to Guide Treatment Decisions in Breast Cancer

October 27, 2023

Praveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.

Experience Helps Guide ILD Prevention/Management With Trastuzumab Deruxtecan in HER2+ Breast Cancer

October 17, 2023

Sneha Phadke, DO, MPH, expands on the investigation of trastuzumab deruxtecan as a possible treatment option for patients with HER2-positive breast cancer who have high-risk residual disease following neoadjuvant systemic therapy.

Durvalumab Plus Guadecitabine Induces Responses in Checkpoint Inhibitor–Naïve ccRCC

April 10, 2023

The combination of durvalumab and guadecitabine generated early signs of clinical activity and tolerability in patients with advanced clear cell renal cell carcinoma, particularly those with no prior exposure to checkpoint inhibitors.

New Breast Center at UI Health Care Aims to Ease the Cancer Journey for Patients

August 22, 2022

The new breast center at UI Holden Comprehensive Cancer Center aims to make the cancer journey easier and less stressful for patients by providing access to the state's most advanced cancer services in 1 convenient location.